ASIA BEAT: Generics the winners in Chinese regulatory overhaul?
This article was originally published in Scrip
As debate continues over Chinese President Xi Jinping's true commitment to meaningful reforms, sweeping draft revisions to drug registration regulations laid out by the China Food and Drug Administration (CFDA) last week show parts of the bureaucracy are already forging ahead.
You may also be interested in...
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.